Augmentation by citalopram of risperidone-induced monoamine release in rat prefrontal cortex

Psychopharmacology

Volumn 185, Issue 3, 2006, Pages 274-281

  Huang, Mei ^a   Ichiwaka, Junji ^a   Li, Zhu ^a   Dai, Jin ^a   Meltzer, Herbert Y ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Citalopram; Depression; Dopamine; Microdialysis; Norepinephrine; Prefrontal cortex; Risperidone; Serotonin

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DOPAMINE; MONOAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; RISPERIDONE; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIALYSATE; DOPAMINE BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MICRODIALYSIS; MONOAMINE RELEASE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RAT STRAIN; RECEPTOR BLOCKING; SEROTONIN BLOOD LEVEL;

ANIMALS; ANTIPSYCHOTIC AGENTS; CITALOPRAM; DOPAMINE; DRUG SYNERGISM; MALE; NOREPINEPHRINE; PIPERAZINES; PREFRONTAL CORTEX; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 33645097092     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0206-1     Document Type: Article

References (73)

1. Ago Y, Sakaue M, Baba A, Matsuda T (2002) Selective reduction by isolation rearing of 5-HT1A receptor-mediated dopamine release in vivo in the frontal cortex of mice. J Neurochem 83:353-359
2. Amsterdam JD, Homig-Rohan M (1996) Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 19:371-386
3. 1A receptors in the rat medial prefrontal cortex: a iontophoretic study. Synapse 17:173-181
4. Barbee JG, Conrad EJ, Jamhour NJ (2004) The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 65:975-981
5. Blier P, De Montigny C, Chaput Y (1990) A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry 51(Suppl):14-21
6. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW (2002) Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl) 160:353-361
7. Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067-1070
8. Corey-Lisle PK, Birnbaum H, Greenberg P, Marynchenko M, Dube S (2003) Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study. Psychopharmacol Bull 37:90-98
9. Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K (2002) Depression: perspectives from affective neuroscience. Annu Rev Psychol 53:545-574
10. Denys D, Klompmakers AA, Westenberg HG (2004) Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacology (Berl) 176:195-203
11. Duman RS (2004) Depression: a case of neuronal life and death? Biol Psychiatry 56:140-145
12. Elhwuegi AS (2004) Central monoamines and their role in major depression. Prog Neuropsychopharmacol Biol Psychiatry 28:435-451
13. Fava M (2001) Augmentation and combination strategies in treatment-resistant depression. J Clin Psychiatry 62(Suppl 18):4-11
14. Fava M, Davidson KG (1996) Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200
15. Felton TM, Kang TB, Hjorth S, Auerbach SB (2003) Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalons and frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 367:297-305
16. Ferrier IN (1999) Treatment of major depression: is improvement enough? J Clin Psychiatry 60(Suppl 6):10-14
17. Frazer A (1997) Antidepressants. J Clin Psychiatry 58(Suppl 6):9-25
18. Gobert A, Rivet JM, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ (1998) Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of free-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor mediated control release. Neuroscience 84:413-429
19. 2-adrenergic receptors underlie its actions. Neuroscience 93:1251-1262
20. Hajos-Korcsok E, Mcquade R, Sharp T (1999) Influence of 5-HT1A receptors on central noradrenergic system activity: microdialysis studies using MDL 73005EF and its enantiomers. Neuropharmacology 38:299-306
21. Hatanaka K, Nomura T, Hidaka K, Takeuchi H, Yatsugi S, Fujii M, Yamaguchi T (1996) Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity Neuropharmacology 35:1621-1626
22. Hatanaka K, Yatsugi S, Yamaguchi T (2000a) Effect of acute treatment with YM992 on extracellular serotonin levels in the rat frontal cortex. Eur J Pharmacol 395:23-29
23. Hatanaka K, Yatsugi S, Yamaguchi T (2000b) Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex. Eur J Pharmacol 395:31-36
24. Hertel P, Fagerquist MV, Svensson TH (1999) Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by α2 adrenoceptor blockade. Science 286:105-107
25. Hertel P, Nomikos GG, Iurlo M, Svensson TH (1996) Risperidone: regional effects in vivo on release and metabolism of dopamine and serotonin in the rat brain. Psychopharmacology (Berl) 124:74-86
26. Hertel P, Nomikos GG, Schilstrom B, Arborelius L, Svensson TH (1997) Risperidone dose-dependently increases extracellular concentrations of serotonin in the rat frontal cortex: role of α2-adrenoceptor antagonism. Neuropsychopharmacology 17:44-55
27. Hirose S, Ashby CR Jr (2002) An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry 63:733-736
28. Ichikawa J, Meltzer HY (1999) R()-8-OH-DPAT, a serotonin 1A receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 291:1227-1232
29. Ichikawa J, Kuroki T, Dai J, Meltzer HY (1998) Effects of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 351:163-171
30. Ichikawa J, Dai J, Meltzer HY (2001a) DOI, a 5-HT2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res 907:151-155
31. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
32. Ichikawa J, Li Z, Dai J, Metlzer HY (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 956:349-357
33. 1A receptor antagonist on citalopram-induced increase in extracellular serotonin in the frontal cortex, striatum and dorsal hippocampus. Neuropharmacology 36:467-473
34. Iyer RN, Bradberry CW (1996) Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 277:40-47
35. Jordan S, Kramer GL, Zukas PK, Moeller M, Petty F (1994) In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse 18:294-297
36. Kerr EA, McGlynn EA, Van Vorst KA, Wickstrom SL (2000) Measuring antidepressant prescribing practice in a health care system using administrative data: implications for quality measurement and improvement. Jt Comm J Qual Improv 26:203-216
37. Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP (2002) R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study. Neuropsychopharmacology 27:949-959
38. Koch S, Perry KW, Bymaster FP (2004) Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 46:232-242
39. Kurose Y, Terashima Y (1999) Histamine regulates food intake through modulating noradrenaline release in the para-ventricular nucleus. Brain Res 828:115-118
40. Leonard BE (1996) New approaches to the treatment of depression. J Clin Psychiatry 57(Suppl 4):26-33
41. Li XM, Perry KW, Wong DT, Bymaster FP (1998) Olanzapine increased in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 136:153-161
42. Matsumoto M, Togashi H, Mori K, Ueno K, Miyamoto A, Yoshioka M (1999) Characterization of endogenous serotonin-mediated regulation of dopamine release in the rat prefrontal cortex. Eur J Pharmacol 383:39-48
43. Meltzer HY (1990) Role of serotonin in depression. Ann N Y Acad Sci 600:486-500
44. Meltzer HY, Maes M (1995) Effect of pindolol pretreatment on MK-212-induced plasma cortical and prolactin responses in normal men. Biol Psychiatry 38:310-318
45. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255
46. Meltzer HY, Li Z, Kaneda Y, Ichiwaka J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172
47. Millan MJ, Gorbert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: I. receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:565-580
48. Nelson JC (1999) A review of efficacy of serotonergic and noradrenergic reuptake inhibitors for treatment of major depression. Biol Psychiatry 46:1301-1308
49. O'Connor M, Silver H (1998) Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol 18:89-91
50. Ostroff RB, Nelson JC (1999) Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 60:256-259
51. Owen JC, Whitton PS (2003) Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat: the involvement of alpha 2 and 5-HT1A receptors. Neurosci Lett 348:171-174
52. Owens MJ, Knight DL, Nemeroff CB (2001) Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50:345-350
53. Parker G, Malhi G (2001) Are atypical antipsychotic drugs also atypical antidepressants. Aust N Z J Psychiatry 35:631-638
54. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic, New York
55. Pozzi L, Invernizzi R, Cervo L, Vallebuona F, Samanin R (1994) Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem 63:195-200
56. Pozzi L, Invernizzi R, Garavaglia C, Samanin R (1999) Floxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin: a comparison with citalopram. J Neurochem 73:1051-1057
57. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39
58. Sanchez C, Hyttel J (1999) Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. Cell Mol Neurobiol 19:467-489
59. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57-73
60. Shelton RC (1999) Treatment options for refractory depression. J Clin Psychiatry 60(Suppl 4): 57-61
61. Shelton RC (2003) The use of antidepressants in novel combination therapies. J Clin Psychiatry 64(Suppl 2):14-18
62. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134
63. Shi L, Namjoshi MA, Swindle R, Yu X, Risser R, Baker RW, Tohen M (2004) Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 26:125-134
64. Stoll Al, Haura G (2000) Tranylcypromine plus risperidone for treatment-refractory major depression [letter]. J Clin Psychopharmacol 20:495-496
65. Szabo ST, Blier P (2002) Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5HT (2A) receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 302:983+IBM-991
66. Tanda G, Carboni E, Fran R, Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential? Psychopharmacology (Berl) 115:285-288
67. Tani K, Takei N, Kawai M, Suzuki K, Sekine Y, Toyoda T, Minabe Y, Mori N (2004) Augmentation of milnacipran by risperidone in treatment for major depression. Int J Neuropsychopharmacol 7:55-58
68. Thase ME (2002) What role do atypical antipsychotic drugs have in treatment-resistant depression. J Clin Psychiatry 63:95-103
69. Tohen M, Vieta E, CalabreseJ, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A (2003) Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar depression. Arch Gen Psychiatry 60:1079-1088
70. Willins DL, Meltzer HY (1997) Direct injection of 5-HT2A receptor agonists into medial prefrontal cortex produced a head-twitch response in rats. J Pharmacol Exp Ther 282:699-706
71. Yoshino T, Nisijima K, Shioda K, Yui K, Katoh S (2004) Perospirone, a novel atypical atypical antipsychotic drug, potentiates flouxetine-induced increases in dopamine levels via multireceptor actions in the rat medial prefrontal cortex. Neurosci Lett 364:16-21
72. Zhang W, Perry KW, Wong DT, Potts BD, Bao JQ, Tollefson GD, Bymaster FP (2000) Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23:250-262
73. Zemlan FP, Garver DL (1990) Depression and antidepressant therapy: receptor dynamics. Prog Neuropsychopharmacol Biol Psychiatry 14:503-523